358 related articles for article (PubMed ID: 25740829)
1. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
[TBL] [Abstract][Full Text] [Related]
2. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.
Seror R; Nocturne G; Lazure T; Hendel-Chavez H; Desmoulins F; Belkhir R; Ravaud P; Benbijja M; Poirier-Colame V; Taoufik Y; Mariette X
Arthritis Res Ther; 2015 Sep; 17(1):241. PubMed ID: 26336930
[TBL] [Abstract][Full Text] [Related]
3. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.
Quartuccio L; Salvin S; Corazza L; Gandolfo S; Fabris M; De Vita S
Clin Exp Rheumatol; 2016; 34(2):311-4. PubMed ID: 26886154
[TBL] [Abstract][Full Text] [Related]
6. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
[TBL] [Abstract][Full Text] [Related]
8. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
9. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
[TBL] [Abstract][Full Text] [Related]
10. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
Kadavath S; Bobic S; Efthimiou P
Clin Rheumatol; 2015 Sep; 34(9):1651-2. PubMed ID: 25652332
[TBL] [Abstract][Full Text] [Related]
11. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
12. Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures.
Carrillo-Ballesteros FJ; Palafox-Sánchez CA; Franco-Topete RA; Muñoz-Valle JF; Orozco-Barocio G; Martínez-Bonilla GE; Gómez-López CE; Marín-Rosales M; López-Villalobos EF; Luquin S; Castañeda-Chávez A; Oregon-Romero E
Clin Exp Med; 2020 Nov; 20(4):615-626. PubMed ID: 32506205
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome.
Hansen A; Reiter K; Ziprian T; Jacobi A; Hoffmann A; Gosemann M; Scholze J; Lipsky PE; Dörner T
Arthritis Rheum; 2005 Jul; 52(7):2109-19. PubMed ID: 15986367
[TBL] [Abstract][Full Text] [Related]
15. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome.
Daridon C; Devauchelle V; Hutin P; Le Berre R; Martins-Carvalho C; Bendaoud B; Dueymes M; Saraux A; Youinou P; Pers JO
Arthritis Rheum; 2007 Apr; 56(4):1134-44. PubMed ID: 17393395
[TBL] [Abstract][Full Text] [Related]
17. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.
Ittah M; Miceli-Richard C; Eric Gottenberg J; Lavie F; Lazure T; Ba N; Sellam J; Lepajolec C; Mariette X
Arthritis Res Ther; 2006; 8(2):R51. PubMed ID: 16507175
[TBL] [Abstract][Full Text] [Related]
18. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome.
Verstappen GM; Kroese FG; Meiners PM; Corneth OB; Huitema MG; Haacke EA; van der Vegt B; Arends S; Vissink A; Bootsma H; Abdulahad WH
J Rheumatol; 2017 Jan; 44(1):49-58. PubMed ID: 28042126
[TBL] [Abstract][Full Text] [Related]
19. Decreased BAFF Receptor Expression and Unaltered B Cell Receptor Signaling in Circulating B Cells from Primary Sjögren's Syndrome Patients at Diagnosis.
Neys SFH; Verstappen GM; Bootsma H; Kroese FGM; Hendriks RW; Corneth OBJ
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563492
[TBL] [Abstract][Full Text] [Related]
20. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
